Aortic Repair Devices Market Size, Share, Growth, Trends, and Global Industry Analysis:  By Device Type (Endovascular Stent Grafts, Surgical Grafts, Stents, Catheters and Delivery Systems, Accessories, Others), By Procedure Type (Endovascular Aneurysm Repair (EVAR), Thoracic Endovascular Aortic Repair (TEVAR), Open Surgical Repair), By Based on the End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), and Region Forecast 2020-2031

Aortic Repair Devices Market size was valued at US$ 3,128.2 million in 2024 and is expected to reach US$ 5,718.5 million by 2031, growing at a significant CAGR of 9.0% from 2025-2031. Moreover, the U.S. global market is projected to grow at 8.6% over the forecast period. The aortic repair devices market refers to the global industry focused on the development, manufacturing, and distribution of medical devices used to treat aortic diseases and disorders, such as aneurysms, dissections, and traumatic injuries. These devices, which include endovascular stent grafts, surgical grafts, and related accessories, are designed to repair or replace damaged sections of the aorta to restore normal blood flow and prevent life-threatening complications. The market encompasses both minimally invasive and open surgical solutions, serving the needs of cardiovascular surgeons, interventional radiologists, and healthcare facilities worldwide.

The aortic repair devices market is experiencing steady growth, driven by rising incidences of aortic aneurysms, an aging global population, and advancements in endovascular repair technologies. Increased adoption of minimally invasive procedures, which offer reduced recovery time and lower complication risks, is a significant growth factor. Technological innovations, such as next-generation stent grafts with enhanced durability and customized designs, are expanding treatment options for complex aortic anatomies. Additionally, growing awareness, improved screening programs, and expanding healthcare infrastructure in emerging economies are creating new opportunities for market expansion, while regulatory challenges and high procedure costs remain key restraints.

Facts & Figures 

• In fact,
• In the EUROSTAR registry (1,190 EVAR patients), 7.1% required conversion to open repair and 2.4% had aneurysm rupture within 8 years.
• The same registry reported only 48% of patients remained free from both conversion and rupture at 8 years.
• A 10-year follow-up study (543 patients, single stent system) showed 96.1% technical success and 1.5% perioperative mortality.
• In that study, 72% of patients remained free from reintervention at 10 years.
• Long-term survival with the Zenith graft: 93% at 1 year, dropping to 9% at 16 years.
• Rupture-free survival with the Zenith graft: 100% at 1 year and 79% at 16 years.

Key Developments

• In May 2023, the RelayPro was introduced, delivering exceptional clinical performance with the lowest commercially available profile. It is approved for treating all pathologies of the descending thoracic artery, including aneurysms, penetrating atherosclerotic ulcers, transections, and dissections. The RelayPro is designed to provide unmatched accuracy, proven efficacy, and long-term durability, along with the broadest selection of sizes, tapering, and configurations available in the market. Its advanced design aims to expand the scope of thoracic endovascular aortic repair (TEVAR) to include patients with smaller access vessels, thereby broadening treatment options and improving patient outcomes.
• In January 2024, L. Gore & Associates announced that the U.S. FDA had approved its Excluder Thoracoabdominal Branch Endoprosthesis (TAMBE). This device serves as an off-the-shelf endovascular solution specifically designed for the treatment of complex aneurysmal disease affecting the visceral segment of the aorta. Its approval marks a significant advancement in addressing challenging thoracoabdominal aortic conditions through minimally invasive techniques.

Aortic Repair Devices Market Segmentation

Based on the device type

• Endovascular Stent Grafts
• Surgical Grafts
• Stents
• Catheters and Delivery Systems
• Accessories
• Others

Endovascular stent grafts are anticipated to be the leading driver in the aortic repair devices market due to their minimally invasive nature and high clinical efficacy. These devices allow physicians to treat complex aortic aneurysms and dissections with reduced surgical risks, shorter hospital stays, and faster patient recovery compared to traditional open surgery. Continuous innovations, such as branched and fenestrated stent grafts, enable treatment of challenging anatomies, expanding their applicability. Rising adoption of these advanced grafts in North America and Europe, supported by growing awareness and reimbursement frameworks, positions endovascular stent grafts as a key growth factor driving overall market expansion.

Based on the procedure type

• Endovascular Aneurysm Repair (EVAR)
• Thoracic Endovascular Aortic Repair (TEVAR)
• Open Surgical Repair

Endovascular Aneurysm Repair (EVAR) is anticipated to be the leading procedure type driving growth in the aortic repair devices market. EVAR offers a minimally invasive alternative to traditional open surgery, reducing operative risks, shortening hospital stays, and enabling faster patient recovery. Technological advancements in stent grafts and delivery systems have expanded EVAR’s applicability to complex abdominal aortic aneurysms, increasing its adoption among vascular surgeons. Strong clinical outcomes, coupled with growing patient preference for less invasive procedures, particularly in North America and Europe, position EVAR as the most influential factor fueling market expansion and establishing it as the preferred method of aortic repair worldwide.

Based on the end user

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Hospitals are anticipated to be the leading end-user segment driving the growth of the aortic repair devices market. Equipped with advanced surgical infrastructure, specialized cardiovascular departments, and highly skilled surgeons, hospitals are the primary centers for performing complex aortic repair procedures, including EVAR and TEVAR. The availability of hybrid operating rooms and sophisticated imaging technologies further enhances procedural efficiency and safety. Additionally, hospitals benefit from robust reimbursement frameworks and established patient inflow, enabling higher adoption of advanced devices such as endovascular stent grafts. This combination of clinical capability and resource availability positions hospitals as the key driver supporting market expansion globally.